Evidence map›Paper›PMID 40948471›Full record

ArticleRenal failure2025

A novel

Ting Peng, Dan Chang, Tingyu Chen, Sipei Chen, Li Wang, Guisen Li

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ting PengDepartment of Nephrology and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Dan ChangDepartment of Nephrology and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID 0009-0005-5365-9065
Tingyu ChenDepartment of Nephrology and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Sipei ChenDepartment of Nephrology and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Li WangDepartment of Nephrology and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Guisen LiDepartment of Nephrology and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein L1 (APOL1) risk variants are strongly associated with kidney diseases, including focal segmental glomerulosclerosis (FSGS), though known mutations (G1/G2) are primarily observed in African populations. This study reports a novel APOL1 mutation (p.T272I) identified in a pair of Chinese twins with FSGS, expanding the genetic spectrum of APOL1-related nephropathies. Whole exome sequencing detected the APOL1 mutation in the twins and excluded parental inheritance. Functional studies demonstrated that transfection of mutant APOL1 into human podocytes and HEK293T cells led to cytoplasmic lysis, disrupted F-actin organization, and reduced expression of nephrin and synaptopodin. The variant also induced mitochondrial dysfunction, increased the LC3-II/I ratio, activated p38 MAPK signaling, and altered chloride channel activity. Structural modeling

Indexed as

Apolipoprotein L1Glomerulosclerosis, Focal SegmentalPodocytesChinaEast Asian PeopleExome SequencingFemaleHEK293 CellsHumansMaleMutationAPOL1 protein, humanApolipoprotein L1Apolipoprotein L1chloride channelcytoskeletonfocal segmental glomerulosclerosispodocyte

Identifiers

PMID40948471
PMCPMC12439807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.